What is PBD Biotech?
PBD Biotech is at the forefront of developing novel phage-based diagnostic technology specifically for veterinary applications. Their proprietary technology is designed to detect critical mycobacteria, including Mycobacterium Bovis (responsible for bovine tuberculosis) and Mycobacterium avium subsp. paratuberculosis (MAP), which causes Johne's disease. These pathogens represent substantial threats to animal health and agricultural productivity, making PBD Biotech's innovations crucial for the industry.
How much funding has PBD Biotech raised?
PBD Biotech has raised a total of $3.2M across 1 funding round:
Unspecified
$3.2M
Unspecified (2021): $3.2M with participation from Mercia Group and Foresight Group
Key Investors in PBD Biotech
Mercia Group
Mercia Group is an investment firm that provides capital and support to businesses, often focusing on technology and innovation-driven companies.
Foresight Group
Foresight Group is a leading independent infrastructure and private equity investment manager, known for backing growth-stage companies.
What's next for PBD Biotech?
The recent major strategic investment signals a pivotal growth phase for PBD Biotech. This capital infusion is expected to accelerate the development and commercialization of their diagnostic solutions, potentially expanding their market reach within the global veterinary diagnostics landscape. The company's focus on addressing significant agricultural health challenges positions it for continued advancement and impact.
See full PBD Biotech company page
